RAPT Q2 2023 Earnings Report
Key Takeaways
RAPT Therapeutics reported a net loss of $25.3 million for the second quarter of 2023, compared to a net loss of $19.2 million for the same period in 2022. The company's research and development expenses increased to $21.6 million, and general and administrative expenses increased to $6.7 million. As of June 30, 2023, the company had cash, cash equivalents and marketable securities of $205 million.
Net loss for the second quarter of 2023 was $25.3 million.
Research and development expenses for the second quarter of 2023 were $21.6 million.
General and administrative expenses for the second quarter of 2023 were $6.7 million.
The Company had cash, cash equivalents and marketable securities of $205 million as of June 30, 2023.
RAPT
RAPT
Forward Guidance
With the current cash balance, the company expects to be able to support operations through mid-2025.